2496 — Wuhan YZY Biopharma Co Balance Sheet
0.000.00%
Last trade - 00:00
- HK$1.45bn
- HK$1.33bn
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | ARS |
Standards: | IFRS | IFRS | IFRS |
Status: | Final | Final | Final |
Cash | |||
Cash and Equivalents | |||
Short Term Investments | |||
Cash and Short Term Investments | 103 | 201 | 197 |
Net Total Receivables | 0.328 | 0.337 | 16.2 |
Total Inventory | |||
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 126 | 239 | 250 |
Gross Property, Plant And Equipment | |||
Accumulated Depreciation | |||
Net Property, Plant And Equipment | 60.1 | 54.7 | 50.5 |
Long Term Investments | |||
Long Term Notes Receivable | |||
Total Assets | 200 | 303 | 302 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Current Portion of Long Term Debt / Capital Leases | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 56.9 | 147 | 174 |
Capital Lease Obligations | |||
Total Long Term Debt | |||
Total Debt | |||
Total Liabilities | 57 | 147 | 174 |
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Total Equity | 143 | 156 | 128 |
Total Liabilities & Shareholders' Equity | 200 | 303 | 302 |
Total Common Shares Outstanding |